AtriCure (NASDAQ:ATRC) Stock Gets Price Target Boost from Citizens Jmp

Key Points

• Citizens Jmp raised AtriCure’s price target from $52 to $68 while maintaining a “market outperform” rating, implying 17.91% upside from the prior close. Other analysts also raised targets, though the overall consensus remains “Hold” with a $55.70 target.
• AtriCure shares rose 3.9% to $57.67, near their 52-week high of $61.70. The company reported quarterly revenue of $153.6 million and EPS of $0.18, exceeding analysts’ revenue expectations.
• Institutional ownership is substantial at 99.11%, including new positions from BlackRock and Bank of America, while insiders sold 74,868 shares worth approximately $3.3 million over the past 90 days.

AtriCure (NASDAQ:ATRC - Get Free Report) had its target price boosted by equities research analysts at Citizens Jmp from $52.00 to $68.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a "market outperform" rating on the medical device company's stock. Citizens Jmp's price objective points to a potential upside of 17.91% from the company's previous close.

A number of other analysts have also commented on the stock. BTIG Research boosted their price objective on shares of AtriCure from $55.00 to $63.00 and gave the stock a "buy" rating in a research report on Monday, October 12th. Piper Sandler lifted their price objective on shares of AtriCure from $50.00 to $60.00 and gave the stock an "overweight" rating in a research report on Thursday, August 27th. Weiss Ratings upgraded AtriCure from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, October 8th. Needham & Company LLC boosted their price target on AtriCure from $45.00 to $64.00 and gave the company a "buy" rating in a research note on Wednesday, September 2nd. Finally, Freedom Capital downgraded shares of AtriCure from a "strong-buy" rating to a "hold" rating in a research note on Friday, October 2nd. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, AtriCure currently has a consensus rating of "Hold" and a consensus price target of $55.70.

AtriCure Trading Up 3.9%

NASDAQ:ATRC opened at $57.67 on Wednesday. The business's 50-day moving average price is $53.28 and its two-hundred day moving average price is $38.68. AtriCure has a 1-year low of $25.36 and a 1-year high of $61.70. The firm has a market capitalization of $2.93 billion, a price-to-earnings ratio of 274.63 and a beta of 1.24. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%. The business had revenue of $153.60 million for the quarter, compared to analysts' expectations of $151.80 million. During the same quarter in the previous year, the business posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities analysts expect that AtriCure will post 0.29 earnings per share for the current year.

Insider Transactions at AtriCure

In other AtriCure news, Director Sven Wehrwein sold 25,000 shares of the stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total transaction of $946,000.00. Following the transaction, the director directly owned 40,518 shares in the company, valued at approximately $1,533,201.12. This represents a 38.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Vinayak Doraiswamy sold 6,000 shares of the stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total transaction of $233,280.00. Following the transaction, the insider directly owned 86,511 shares in the company, valued at $3,363,547.68. This trade represents a 6.49% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 74,868 shares of company stock valued at $3,317,897. 4.00% of the stock is owned by insiders.

Institutional Trading of AtriCure

A number of institutional investors and hedge funds have recently modified their holdings of ATRC. BlackRock Inc. bought a new stake in shares of AtriCure in the 2nd quarter worth approximately $125,198,000. Bank of America Corp DE purchased a new position in AtriCure in the 2nd quarter worth approximately $24,465,000. Grandeur Peak Global Advisors LLC bought a new position in AtriCure during the second quarter valued at approximately $16,435,000. Osterweis Capital Management Inc. bought a new position in shares of AtriCure during the second quarter valued at about $14,028,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of AtriCure in the second quarter worth $9,388,000. 99.11% of the stock is owned by hedge funds and other institutional investors.

About AtriCure

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company's product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.